Featured Articles

Merck announced that the company is beginning two Phase 3 studies of PCV-15 (V114), its investigational polyvalent conjugate vaccine for the prevention of pneumococcal disease. The…
Read More...

Shire plc announces that it has entered into a definitive agreement with Servier S.A.S. to sell its Oncology business for $2.4 billion. Shire's Oncology business includes in-market…
Read More...

Sobi has received approval from Health Canada for a reduced dosing frequency for Orfadin (nitisinone). Orfadin is approved in combination with dietary restriction of tyrosine and…
Read More...

Almac Group announced that it has expanded its US commercial packaging capabilities at its Audubon, PA facility. Addressing increased client demand of developing and bringing more…
Read More...

BioAscent Discovery Limited has announced the launch of a comprehensive suite of integrated drug discovery services with immediate effect. Dr Phil Jones will be joining as Chief…
Read More...

MilliporeSigma announced a partnership with Oxford University's Jenner Institute to develop more robust and scalable vaccine manufacturing processes. This partnership, as well as plans…
Read More...

GSK and Orchard Therapeutics announced a strategic agreement, under which GSK will transfer its portfolio of approved and investigational rare disease gene therapies to Orchard,…
Read More...

Ionis Pharmaceuticals announced that it has licensed IONIS-AZ6-2.5-LRx, or AZD2693, to AstraZeneca following advancement of the drug into development. IONIS-AZ6-2.5-LRx is designed to…
Read More...

Lonza is opening the world’s largest dedicated cell-and-gene-therapy facility, which was built in anticipation of the rising demand from developers of cell and gene therapies – the next…
Read More...

Halo Pharma, a rapidly growing contract development and manufacturing organization (CDMO), offers more than 30 years’ direct experience in the production of topical drug products – from…
Read More...

Novartis announced that the US Food and Drug Administration (FDA) has approved Afinitor DISPERZ (everolimus tablets for oral suspension), for the adjunctive treatment of adult and…
Read More...

Allele Biotechnology & Pharmaceuticals Inc. has received a Tissue Bank License from the California Department of Public Health, making it the world’s first establishment to collect…
Read More...

Ferring Pharmaceuticals and Rebiotix Inc. announce that they have agreed to the acquisition of Rebiotix by Ferring. This acquisition brings together two innovative healthcare companies…
Read More...

Boehringer Ingelheim and OSE Immunotherapeutics announced a collaboration and exclusive worldwide collaboration and license agreement to jointly develop OSE-172, a SIRP-alpha antagonist…
Read More...

AstraZeneca and MedImmune announced that the US Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for moxetumomab pasudotox, an investigational…
Read More...

Abide Therapeutics announced that it has granted Celgene an exclusive worldwide license for ABX-1772, a preclinical drug candidate discovered by Abide. In connection with the license,…
Read More...

Pharmaceutical Product Development, LLC (PPD) has expanded its GMP (good manufacturing practices) analytical laboratory in Middleton, Wisconsin. PPD Laboratories’ new 32,000-square-foot…
Read More...

Abzena plc, the life sciences group providing services and technologies to enable the design, development and manufacture of biopharmaceutical products, has announced the completion of…
Read More...

GlaxoSmithKline plc announces that it has reached an agreement with Novartis for the buyout of Novartis’ 36.5% stake in their Consumer Healthcare Joint Venture for $13 billion (£9.2…
Read More...

ViiV Healthcare announced that the European Committee for Medicinal Products for Human Use (CHMP) has issued a Positive Opinion recommending marketing authorisation for Juluca…
Read More...